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Surfactant protein D (SP-D) mediates clearance of microorganisms and modulates inflammation in
response to cytotoxic stimulation. It is present in various epithelia, but also in vascular smooth mus-
cle and endothelial cells. Experiments were designed to determine whether or not SP-D is present in
porcine coronary arterial endothelial cells and if so, to investigate the molecular mechanisms underlying
this presence. The expression of SP-D, NO synthase, Akt 1/2 and Erk 1/2 proteins was determined in cul-
tures at passages 1 (#1) and 4 (#4). SP-D in primary cells existed in three isoforms (37–38kDa and 50kDa).
The 37–38kDa SP-D forms were the dominant isoforms in the porcine endothelium and were prominent
at #1 but partially lost at #4. Tumor necrosis factor- (TNF-) significantly augmented the level of SP-D
expression at #1 but not at #4. The basal level of 37–38kDa SP-D isoforms at #1 was reduced by L-NAME,
wortmannin and PD 98059. The low basal expression at #4 could be increased by DETA NONOate (donor
of NO) or insulin (activator of PI3K/Akt). The presence of nitric oxide synthase was reduced while that
of Akt 1/2 and Erk 1/2 was increased at #4. In cells both at passages 1 and 4, TNF- downregulated NO
synthase and up-regulated p-Erk 1/2 protein. The present findings demonstrate the presence of SP-D in
endothelial cells which is NO-, PI3K/Akt- and Erk-dependent. They suggest a protective role of SP-D in
these cells.
© 2008 Elsevier Ltd. All rights reserved.
1. Introduction
Surfactant protein D (SP-D) is a collectin involved in the innate
immune defense of epithelial surfaces including the lung (Motwani
et al., 1995; Madsen et al., 2000). Pulmonary SP-D is produced by
alveolar type II and Clara cells and secreted to the alveolar surface.
The carbohydrate recognition domain of SP-D binds specifically to
the surface of pathogenic microorganisms to initiate their elimina-
tion by aggregation, opsonization for phagocytosis or direct lysis
of the microbial cell membrane (Holmskov et al., 2003; Kingma
and Whitsett, 2006). In the mouse, the SP-D knockout phenotype
is characterized by alveolar infiltrations with leucocytes and foam
cells, increased levels of proinflammatory cytokines and metallo-
proteinases and the spontaneous development of emphysema. The
production of SP-D increases during development, is under hor-
monal influences, and is up-regulated in pulmonary inflammatory
diseases (Holmskov et al., 2003; Sorensen et al., 2007). Moreover,
low systemic levels of SP-D are correlated to obesity in humans
(Sorensen et al., 2006; Zhao et al., 2007).
∗ Corresponding author. Tel.: +852 2819 9258; fax: +852 2817 0859.
E-mail address: vanhoutt@hkucc.hku.hk (P.M. Vanhoutte).
SP-D is further localized to mucosal surfaces in non-pulmonary
tissues like the gastrointestinal tracts and genital system (Bourbon
and Chailley-Heu, 2001; Leth-Larsen et al., 2004). SP-D is also
present in endothelial and vascular smooth muscle cells of humans
and mice (Sorensen et al., 2005; Snyder et al., 2008). In human vas-
cular smooth muscle cells, it exerts an anti-inflammatory action
(Snyder et al., 2008). The role of SP-D in endothelial cells is
unknown.
Nitric oxide produced by the endothelial cells helps to control
vascular tone and maintain an anti-inflammatory and anti-
thrombotic surface within the vasculature (Moncada et al., 1991;
Flavahan, 1992; Vanhoutte, 2003). The turnover and resulting
regeneration of endothelial cells in vivo can be accelerated by
mechanical disruption (Shimokawa et al., 1987; Lee et al., 2007).
Cultures derived from regenerated endothelium are dysfunctional
with reduced NO synthesis, enhanced apoptosis (Lüscher and Noll,
1995; Tschudi et al., 1996; Asai et al., 2000; Vanhoutte et al.,
2002; Lee et al., 2007), and genomic changes compatible with
increased oxidative stress and reduced anti-coagulant properties
(Lee et al., 2007). This dysfunction probably favors the develop-
ment of atherosclerosis (Hoffmannet al., 2001; Brandes et al., 2005;
Lee et al., 2007). The endothelial dysfunction of regeneration can
be mimicked by multiple passaging in vitro as regards reduced
0161-5890/$ – see front matter © 2008 Elsevier Ltd. All rights reserved.
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nitric oxide bioavailability in terms of cyclic GMP production and
increased oxidative stress (Rubin, 1997; Antropova et al., 2000; Shi
et al., 2004). Akt and Erk are involved in the activation of eNOS and
augmented the release of nitric oxide by various stimuli includ-
ing shear stress, insulin and estrogens (Jin et al., 2005; Joy et al.,
2006), resulting in the release of nitric oxide. They also promote
endothelial survival and proliferation after inflammatory stimula-
tion (Zhang et al., 2001; Secchiero et al., 2003).When the cellswere
activated by inflammatory cytokines, in particular tumor necro-
sis factor- (TNF-), both Akt and Erk are activated and mediate
the signaling leading to stress-induced apoptosis (Secchiero et al.,
2003; Chen and Easton, 2008).
The present experiments were designed to test the hypothe-
sis that endothelial dysregulation would result in reduced SP-D
expression. Endothelial dysregulation was induced by culture after
multiple passaging and quantified by diminishing and inhibit-
ing NO-synthase, and measuring Erk and Akt kinase activity. The
experiments were performed on endothelial cells from the porcine
coronary artery since the coronary circulation in that species
closely resembles that of the human.
2. Materials and methods
2.1. Cell isolation and primary culture
The present study was approved by the Committee on the Use
of Live Animals in Teaching & Research of The University of Hong
Kong. Female pigs (weight 25–30kg)were anaesthetized and euth-
anized by exsanguination. The heart was removed and placed in
fetal bovine serum (FBS)-containing culture medium. The aorta
and coronary arteries were excised, cleaned of surrounding fat
and connective tissue, and opened longitudinally. Endothelial cells
were harvested by gentle scraping of the luminal surface using a
scalpel blade (Lee et al., 2007). They were either studied with-
out further culture (both aortic and coronary endothelial cells)
or seeded (coronary endothelial cells only) on collagen type I-
coated culture plates for mRNA and protein analysis (Lee et al.,
2007). The cultures were maintained in Eagle’s minimal essential
medium (Gibco-BRL; Grand Island, NY, USA) containing 10% FBS,
and penicillin–streptomycin (100unit/ml) and kept at 37 ◦C, 95%
humidity, 5% CO2. The medium was changed every 48h until the
cells reached confluence (passage 0). Cells were detached for pas-
saging with trypsin–EDTA and were passaged on a weekly basis at
a ratio of 1:3 to produce cells at passage 1 (#1).
Cultured cells were passaged (split at 1:3 ratio; 100mm2 plate)
further weekly until cells at passage 4 (#4) were obtained. After
reaching 70–80% confluence (which takes 2–3 days after sub-
culture), cells were changed into FBS-free medium for 30min
prior to drug treatment. Cells at #1 and #4 were exposed to
TNF- (10ng/ml) for 2h. For inhibition experiments, cells at #1
were treated with either N-nitro-l-arginine methyl ester (L-NAME;
100M), wortmannin (20nM) or PD 98059 (50M) for both
2h and 4h. For stimulation experiments, diethylenetetraamine
NONOate (DETA NONOate; 100M) and insulin (1nM) were
administered for 4h in cells at #4. The presence of SP-D was
detected by Western blotting after the various drug treatments.
2.2. Isolation of porcine lung homogenates for immunoblotting
Lung tissue was homogenized in buffer (10mM Tris–HCl/
100mM NaCl, 0.25M sucrose, 2mM EDTA; pH 7.4) containing a
cocktail of protease inhibitors (10M leupeptin; 10M pepstatin
A and 1mM phenylmethylsulfonyl fluoride) and centrifuged at
200× g at 4 ◦C for 10min to remove cellular debris. The supernatant
was centrifuged at 208,000× g at 4 ◦C for 16h. The pellet was re-
suspended in Tris-buffered saline (TBS) for immunoblotting. The
protein content was quantified using the Bradford Assay.
2.3. RNA preparation and real time-PCR
The total RNA (∼5g to 10g) from cells at #1 and #4, both
under conditions basal and after TNF--stimulation was extracted
with TRIZOL according to the manufacturer’s instructions. One
microgramof total RNAwas added to the reverse transcriptionmix-
ture [(20l; first-strandbuffer, 10mMDTT,0.5mMDNTPs, 10ng/l
Oligo(dT) (Gibco-BRL; Grand Island, NY, USA), 1unit/l Rnasin;,
1 unit/l moloney murine leukemia virus reverse transcriptase
(M-MLV RT; Gibco-BRL, USA)] for 10min at room temperature fol-
lowed by 37 ◦C for 60min. The product was denatured by placing
at 94 ◦C for 7min to produce the first-strand cDNA. One micro-
liter of the total reverse transcription product was added to PCR
reaction mixture (20l) containing 10l 2× SYBR® Green PCR
master mix (Applied Biosystems, UK) and the primers (sense
and anti-sense; 1M) for the polymerase chain reaction (PCR).
Real-time PCR technique was used to determine the mRNA expres-
sion. The PCR products were amplified using a primer pair of
sequence specific oligonucleotides for porcine SP-D carbohydrate
recognition domain (CRD): 5′-CGG AGG GCA ATT TCA CCT AC-
3′ and 5′-TGG CCA GCA GAA GGT CAC-3′ (257bp) (van Eijk et
al., 2000) and GAPDH, 5’-AATGACCCCTTCATTGACCTCC-3’ and 5’-
GCTTCCCATTCTCAGCCTTGAC-3’ (100bp).
Unknown samples and gene-specific PCR products for the stan-
dard (porcine SP-D CRD at different dilutions)were amplified using
a 7900HT Fast Real-Time PCR System (Applied Biosystems; Foster
City, CA, USA). The cycling conditions to amplify PCRproducts of SP-
D CRD and GAPDH when using real time PCR were 50 ◦C for 2min;
95 ◦C for 10min; 95 ◦C for 15 s, 60 ◦C for 1min; and 95 ◦C for 15 s.
Each sample was studied in duplicates. Results were normalized to
the copy numbers of GAPDH gene products in the samples. The PCR
productswere visualized on 1.2% (w/v) agarose gels using ethidium
bromide to ensure that the PCR products produce a single band at
the expected size.
2.4. Western blotting
After treatment with various blockers or activators, cells were
washed twice with cold phosphate buffer solution and then lysed
in ice-cold lysis buffer (20mM Tris–HCl, 1% Triton X-100, 150mM
NaCl, 1mM EDTA, 1mM EGTA, 2.5mM sodium pyrophosphate,
1mM -glycerophosphate, 1mM sodium orthovanadate) contain-
ing a cocktail of protease inhibitors (1mM phenylmethylsulfonyl
fluoride, 100ng/ml trypsin inhibitor, 20g/ml leupeptin and 1M
pepstatin). The protein concentration was determined using the
Bradford Assay. Thirty to 40g of total protein were separated on
a polyacrylamide gel (10%) and blotted on nitrocellulose mem-
branes (200mA, 1.5h). The blot was incubated for 1h in TBS
containing 5% fat-free milk. Membranes were incubated with
antibodies at 4 ◦C overnight. This was followed by incubation of
the HRP-labeled secondary antibody (Amersham; Freiburg, Ger-
many) prior to image detection by enhanced chemiluminescence
using a commercially available kit (Amersham). For SP-D, the
membranes were incubated with 10g/ml mAb 1.7 anti-porcine
SP-D (Soerensen et al., 2005) overnight and then with alkaline
phosphate-coupled goat anti-mouse immunoglobulin (DAKOCy-
tomation; Glostrup, Copenhagen, Denmark) for 2h. The SP-D band
was developed using nitro blue tetrazolium/5-bromo-4-chloro-3-
indolyl phosphate (NBT/BCIP) tablets (Roche, Penzberg, Germany).
For reprobing with antibodies, the nitrocellulose membranes were
incubated at 50 ◦C for 30min in a buffer containing Tris/HCl
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(67.5mM, pH 6.8); -mercaptoethanol (100mM), and sodium
dodecyl sulfate (SDS; 2%, w/v). After extensive washing, the fil-
ters were incubated in blocking buffer and subsequently with the
primary antibody and developed (Fisslthaler et al., 2003).
2.5. Data analysis
Data are expressed as means± S.E.M. The Western blot image
intensity was calculated by the Multi-Analysis computerized
program(Multi-Analyst version1.1; Bio-Rad Laboratories, Inc.;Her-
cules, CA, USA). Densitometric analysis was normalized with the
respectivehouse-keeping gene,GAPDH, or theprotein,-actin. Sta-
tistical analysis of the datawas performed using Student’s t-test for
paired or unpaired observations. P-values equal to or less than 0.05
were considered to indicate statistically significant differences.
2.6. Drugs and reagents
Recombinant human TNF- was obtained from Invitrogen
(Carlsbad, CA, USA). Antibody against porcine SP-D was a kind
gift fromPeter Heegaard (Danish Veterinary Institute, Copenhagen,
Denmark). The antibody against Erk 1/2 (1:1000), captopril and
the Erk/MEK inhibitor PD 98059 were purchased from Calbiochem
(Behring, La Jolla, CA, USA). Antibodies against protein kinase B or
Akt 1/2 (1:1000) and phospho-Erk 1/2 (1:1000) were from Cell Sig-
naling (Beverly, MA, USA). Antibodies against beta-actin (1:2000),
insulin, L-NAME and wortmannin were obtained from Sigma (St.
Louis, MO, USA). Diethylenetetraamine NONOate was purchased
from Cayman (Ann Arbor, MI, USA). The antibody against endothe-
lial nitric oxide synthase (eNOS; 1:2500) was from Transduction
Laboratories (Lexington, KY, USA).
3. Results
3.1. Localization of SP-D in porcine endothelial cells
In the lung homogenates, immunoblotting using the mono-
clonal antibody against porcine SP-D detected a band with a
molecular weight of 50kDa as previously reported (van Eijk et al.,
2002). In freshly collected coronary endothelial cells (Fig. 1) two
bands at 37–38kDa and a single band at 50kDa were detected
by the monoclonal antibody. In addition, immunoreactive proteins
with estimated molecular masses lower than the mass of the intact
protein appeared in the blots at 27–28kDa and at 19kDawith vary-
ing intensity. The 37–38kDa variants were the predominant forms
at #1 (Fig. 1) and 4 (data not shown). The 50kDa variants were
detected only in freshly collected cells but not in cultured cells.
Therefore, only the intensity of the 37–38kDa variants was ana-
lyzed before and after treatments. Cross-reactivity between the
monoclonal anti-SP-D antibody and components in the cell cul-
ture medium was tested using a four times concentrate or FBS. No
cross-reactivity was observed (data not shown).
3.2. Basal and TNF-˛ induced levels of endothelial SP-D
expression is reduced with successive passaging
The endothelial mRNA expression of SP-D was reduced signif-
icantly (by 50%) at #4 compared to #1 (Fig. 2a). Incubation with
TNF- (10ng/ml) for 2h significantly augmented (by 200%) the
expressionof SP-DmRNAat#1. At#4, TNF-no longer caused a sig-
nificant increase in theexpressionof SP-Dusing the same treatment
conditions (Fig. 2b).
The expression level of SP-D protein was significantly reduced
(by 40%) at #4 compared to #1 (Fig. 3a). TNF- augmented the
Fig. 1. Basal detection by Western blotting of SP-D in porcine lung lysates, freshly
collected porcine coronary endothelial cells before and after primary cell culture
(#1). Lanes 1 and 3, lung lysates; lane 2, freshly collected coronary endothelial cells
without culture; lane 4, cultured coronary endothelial cells at #1.
Fig. 2. Basal and stimulated SP-D gene expression in cultured porcine coronary
endothelial cells at #1 and #4. Total RNA from cultured endothelial cells with
or without treatment was harvested for the detection of SP-D carbohydrate-
recognition domain (CRD) gene by real time-PCR. Genetic sequence encoding for
the CRD region of porcine SP-D was selected to give a PCR product of 257bp. (a)
Basal genetic expression of SP-D CRD at passages (#) 1 and 4. Data are expressed as
% change and shown as mean± S.E.M. of the basal level at #1. (b) Stimulated level of
SP-D CRD gene by incubation with tumor necrosis factor (TNF-; 10ng/ml) for 2h
in endothelial cells at passages (#) 1 and 4. Data are expressed as % changes± S.E.M.
from the corresponding vehicle control of the same passage. The asterisk indicates a
statistically significant (P<0.05) difference fromthe corresponding control (n=3–5).
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Fig. 3. Basal and stimulated SP-D protein presence in cultured porcine endothelial
cells at #1 and #4. Total protein from cultured endothelial cells with or without
treatment was harvested, lysed, and processed for SP-D protein detection using
immunoblotting analysis. A monoclonal antibody against porcine SP-D was used to
probe theSP-Dmonomerat approximately37–38kDa. Themembranewere stripped
and reprobedwithantibodyagainst-actin fornormalizationof sample loading. The
representative SP-D protein expression is shown as determined by densitometric
analysis. (a) Upper: the basal SP-D protein at #1 and #4. Lower: data expressed as %
change and shown asmean± S.E.M. from the basal level at #1. (b) Upper: stimulated
level of SP-Dprotein after incubationwithTNF- (10ng/ml) for 2hunder serum-free
condition in endothelial cells at #1 and #4. Ctrl, vehicle; TNF, TNF--treated. Lower:
data expressed as % change and shown as mean± S.E.M. of the corresponding vehi-
cle control from the same passage. The asterisk indicates a statistically significant
(P<0.05) difference from corresponding control (n=5–7).
expression level of SP-D protein significantly at #1 (by 170%), but
not at #4 (Fig. 3b).
3.3. Porcine endothelial SP-D expression is dependent on
endothelial nitric oxide synthase, Akt 1/2 and Erk 1/2
Porcine coronary endothelial cells were treated with various
types of metabolic inhibitors under serum-free medium and time-
dependent responses were obtained at 2-h and 4-h intervals. The
SP-D protein expression was diminished significantly by incuba-
tion with the nitric oxide synthase inhibitor, L-NAME (100M)
(55% reduction, P<0.05), the phosphatidylinositol-3 kinase/Akt
inhibitor, wortmannin (20nM) (75% reduction, P<0.01), and the
Erk/MEK inhibitor, PD98059 (50M)(60%,P<0.05)at the4-h inter-
Fig. 4. Effects of inhibitors of nitric oxide synthase, PI3K/Akt 1/2 and Erk 1/2 on the
basal expression of SP-D protein at #1 and effects of a nitric oxide donor and an
activator of PI3K/Akt on SP-D at #4. (a) Upper: endothelial cells at #1 were treated
with L-NAME (100M),wortmannin (20nM) and PD 98059 (50 (M) under serum-
free conditions at 2-h and 4-h interval. C, vehicle; L, L-NAME; W, wortmannin; P, PD
98059. Lower: data expressed as % change and shown as mean± S.E.M. of the corre-
sponding vehicle control from the same passage (n=3). (b) Upper: endothelial cells
were sub-cultured until #4 and DETA NONOate (100M) and insulin (1nM) were
supplemented under serum-free conditions for 4h. C, vehicle; N, DETA NONOate; I,
insulin. Lower: data expressed as % change and shown as mean± S.E.M. of the cor-
responding vehicle control or basal level at #1 (n=3). No significant difference was
found between basal and vehicle-treated SP-D level at #4. The asterisk indicates a
statistically significant (P<0.05) difference from corresponding control.
val (Fig. 4a). The reduction in SP-D expression at #4 was reversed
partially by incubation for 4h with either the exogenous NO donor,
DETA NONOate (100M) or the PI3K/Akt activator insulin (1nM)
(Fig. 4b).
Western blotting also revealed a significantly reduced basal
expressionof eNOSprotein at#4 compared to#1 (Lee et al., submit-
ted). By contrast, the basal protein levels of both Akt 1/2 and Erk 1/2
were increased significantly at #4 (Fig. 5a and b). Treatment with
TNF- for 2h of cells at #1 significantly reduced the protein level
of eNOS but significantly increased that of Akt 1/2 and p-Erk 1/2
(Fig. 6a–c), compared to the corresponding vehicle controls.
4. Discussion
SP-D is a large and complex protein which exists as structural
variants with different proportions of trimers, dodecamers, and
high multimers (Crouch et al., 1993) probably due to the indi-
vidual polymorphic variation (Leth-Larsen et al., 2005). Different
oligomeric forms of SP-D result in different functions. Thus, SP-
D of high molecular weight binds preferentially to intact viruses
and bacteria, whereas the lowMWSP-D interactswith lipopolysac-
charide (Leth-Larsen et al., 2005; Hartshorn et al., 2007) and this
may lead to differential contribution to inflammation of the dif-
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Fig. 5. Basal detection of (a) Akt 1/2 and (b) Erk 1/2 proteins in cultured porcine
coronary endothelial cells at #1 and#4.Upper: representativeWestern blots. Lower:
data of 5–7 independent experiments expressed as % change between #1 and #4
and shown as means± S.E.M. of the corresponding basal level at #1. The asterisk
indicates a statistically significant (P<0.05) difference from corresponding control.
ferent molecular SP-D forms. However, SP-D may also act in a dual
manner, to enhanceor suppress inflammatorymediatorproduction
depending on its binding orientation with the effectors (Gardai et
al., 2003) as well as the inflammatory status of the host (Janssen et
al., 2008). The present study demonstrates the presence of three
isoforms (37–38kDa and 50kDa) in endothelial cells. SP-D has
likewise been detected in human alveolar lavage (43kDa) with a
higher molecular weight than the 37kDa variant present in human
endothelial cells (Sorensen et al., 2005). The 50kDa form of SP-
D in the porcine coronary endothelial cells was consistent with
the native SP-D being detected in lung of the same species (van
Eijk et al., 2002). However, in primary culture of porcine coronary
endothelial cells, the 50kDa, 27–28kDa and probably the 19kDa
breakdown products were detected at a minimal level while the
37–38kDa form was dominant. This 37–38kDa bands could be due
to proteolytic degradation or alternative glycosylation or a repre-
Fig. 6. Detection of (a) eNOS, (b) Akt 1/2 and (c) p-Erk 1/2 proteins in cultured
porcine coronary endothelial cells at #1 after stimulation with tumor necrosis fac-
tor  (TNF-; 10ng/ml) for 2h under serum-free condition. Upper: representative
Western blots; Ctrl, vehicle; TNF, TNF--treated. Lower: data expressed as % change
and shown asmeans± S.E.M. of the corresponding vehicle control at #1. The asterisk
indicates a statistically significant (P<0.05) difference from corresponding control
(n=3–6).
sentative splice variant form of the intact SP-D polypeptide found
in freshly harvested cells. Due to the low detection level of the
native 50kDa SP-D in cultured endothelial cells, the further studies
focused on the 37–38kDa protein, since it was the dominant SDS-
PAGE product in the present experimental setting. Both the mRNA
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expression and the 37–38kDa SP-D protein expression decreased
from#1 to #4. To further understand the possiblemechanism lead-
ing to the basal expression of SP-D in endothelial cells at #1, the
effects of various blockers, known to cause changes in endothe-
lial responses compatible with dysfunction, were examined on the
expression level of the protein. Since this level was reduced when
the cells were treated with L-NAME [inhibitor of eNOS; Grumbach
et al., 2005],wortmannin [inhibitor of PI3K/Akt; Bernier et al., 2000]
andPD98059 [inhibitor of Erk 1/2; Bernier et al., 2000], nitric oxide,
phosphotidylinositol-3 kinase (PI3K/Akt) and Erk must contribute
to maintain the basal presence of SP-D protein in endothelial cells.
Supplementation with exogenous NO [by DETA NONOate; Braam
et al., 2004] or treatment with insulin [which activates PI3K/Akt;
Fisslthaler et al., 2003]at#4significantly counteracted theeffectsof
in vitropassaging on the expressionof theprotein. Thus, thepresent
observations reveal the importance of nitric oxide in permitting
the basal expression of SP-D in native/young endothelial cells, a
role that diminishes with multiple passaging. To date, it is still not
clear whether or not SP-D can be taken up by endothelial cells from
the systemic circulation especially since nitric oxide can serve as a
facilitator to initiate endocytosis in these cells (Lowenstein, 2007).
Since no protein presence of SP-D could be detected in the cul-
ture medium and FBS, the possibility of its presence by endocytosis
in endothelial cells under culture conditions can be eliminated, at
least in the present study.
The development of atherosclerosis involves a complex pro-
cess of inflammatory and atherothrombotic events which result
in part from endothelial dysfunction and involves an inflamma-
tory response (Ross, 1999; Koh et al., 2005 Libby, 2008). Obesity
is one of the factors that may lead to endothelial dysfunction
(Meyers and Gokce (2007)). Low systemic levels or even lack of
SP-D are associated with obesity in mice and humans, respectively
(Sorensen et al., 2006; Zhao et al., 2007). However, the relation
between SP-D levels, obesity and endothelial dysfunction has not
been investigated. In human vascular smooth muscle cells, SP-
D may play an anti-inflammatory role. Thus, overexpression of
SP-D in these cells enhanced uptake and clearance of pathogens
like C. pneumoniae while the production of IL-8, a proinflamma-
tory mediator, was attenuated (Snyder et al., 2008). The level of
SP-D augmented in response to TNF- and lipopolysaccharide,
suggesting a protective immunomodulating role in inflammatory
situations (Snyder et al., 2008). By contrast to the observations
in human vascular smooth muscle, data obtained in genetically
modified mice suggests that SP-D may play a pro-atherogenic
role. Indeed, atherosclerotic lesions are reduced in homozygous
SPD−/− mice fed an atherogenic diet (Sorensen et al., 2005). Lower
serum TNF- and higher HDL-C levels were measured in the
SPD−/− compared to wild type mice on the same diet, suggesting
a modified lipid metabolism, reduced stimulation of inflamma-
tory processes, and a pro-atherogenic role for SP-D (Sorensen
et al., 2005) in that particular mouse model. The differential
effects of SP-D on inflammatory responses observed in the mouse
(Sorensen et al., 2005) and in human tissues (Snyder et al., 2008)
may reflect species differences and effects specific for the chosen
model system. The present data obtained in porcine endothelial
cells are in line with those reported in human vascular smooth
muscle rather than with the findings in genetically modified
mice.
One of the important physiological roles of the endothelium is
to release nitric oxide as a major factor to control the tone of the
underlying vascular smooth muscle and to prevent events lead-
ing to formation of the atherosclerosic plaque (Moncada et al.,
1991; Joannides et al., 1995; Vanhoutte, 1997). Endothelial cells
undergo aging both in vivo and in vitro (Rubin, 1997). Such aged
cells are viable and metabolically active but display altered gene
and protein expressions, resulting in phenotypic changes (Fournet-
Bourguignon et al., 2000; Brandes et al., 2005). In endothelial cells
at #4, the eNOS protein presence is reduced (Vanhoutte et al.,
2002), indicating a decreased capability to produce nitric oxide,
and thus endothelial dysfunction. Akt 1/2 and Erk 1/2 are involved
in insulin-related and extracellularly regulated signaling pathways,
respectively, to modulate longevity (Secchiero et al., 2003; Qiao et
al., 2004) and promote proliferation. They also activate eNOS to
release nitric oxide (Jin et al., 2005; Joy et al., 2006). Nevertheless,
theAkt activity increaseswith cellular senescence and its inhibition
extends the lifespanofprimary culturedendothelial cells (Miyauchi
et al., 2004). ThemechanismbywhichAktaffects cellular lifespan in
primary cell cultures is complex due to its interactions with several
components of the cell cycle and the regulation of cell death (Zhang
et al., 2001). Nonetheless, it is still not clear why in the present
study the protein presence of Akt 1/2 and Erk 1/2 are increased at
#4 despite the reduced protein presence and activity of nitric oxide
synthase.
TNF-, an inflammatory cytokine, can be produced under
various pathological conditions contributing to endothelial dys-
function and atherosclerosis (Krasinski et al., 2001; Sack, 2002;
Makino et al., 2005; Chen and Easton, 2008). The up-regulation
of SP-D in early passaged endothelial cells in response to TNF-,
observed in the present study both at the genomic transcriptional
and proteomic levelsmay indicate that SP-Dplays an immunomod-
ulating role in host cell defensemechanisms in response to vascular
stress or injury in order to reduce inflammation. The involvement
of SP-D in modulating the response in association with nitric oxide
may help to prevent the shift of nitrosylated components under
inflammatory conditions (Atochina et al., 2004). This phenomenon
is not observed in cells at #4. In line with other studies, the pro-
tein expression of endothelial nitric oxide synthase is reduced
in endothelial cells at #1 (Lee et al., submitted) and #4 when
treated with TNF-, suggesting a detrimental effect on nitric oxide
production by cytotoxic stimulation (Makino et al., 2005). Treat-
ment with TNF- for 2h also induced a significant increase in
Akt 1/2 and p-Erk 1/2 in endothelial cells at #1, promoting cell
survival (Secchiero et al., 2003). The inability to up-regulate SP-
D by TNF- in cells at #4 might be explained by the reduction
in eNOS protein despite activation of p-Erk 1/2 (Hoffmann et al.,
2001; Fisslthaler et al., 2003; Secchiero et al., 2003). As a conse-
quence, theprogressive loss of nitric oxide (Csiszar et al., 2004) after
multiple passaging permits the expression of proinflammatory
mediators, a stage at which the protein presence of SP-D is reduced
concomitantly.
In summary, the present data indicate that SP-D is expressed in
porcine coronary artery endothelial cells in two or three isoforms.
The basal expression level can be augmented in response to TNF-
. The expression of SP-D protein requires the production of nitric
oxide, and is also Akt- and Erk-dependent. Thus, the lower level of
SP-Dproteinobserved in culturedendothelial cells at#4 is probably
related to the reduced production of nitric oxide. These results sug-
gest a possible anti-inflammatory role of SP-D in endothelial cells,
with its role being diminished in dysfunctional cells, as obtained
by multiple passaging. These findings support a favorable role of
SP-D in curtailing processes in the vascular wall facilitating the
occurrence of atherosclerosis.
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